Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial

Journal of Drugs in Dermatology, March, 2006 by Emil Tanghetti, William Abramovits, Barry Solomon, Keith Loven, Alan Shalita

Dr. Tanghetti has conducted clinical trials and is a consultant for Allergan, Inc. and Stiefel Laboratories, Inc. Dr. Abramovits has received research support or is a consultant or lecturer for Allergan, Inc. and Dermik Laboratories. Dr. Solomon has no financial disclosures. Dr. Loven is an investigator for Allergan, Inc. Dr. Shalita is a consultant and investigator for Allergan, Inc. and Stiefel Laboratories, Inc. He is also a consultant for Dermik Laboratories and has been an investigator for Galderma.

References

1. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003; 49(1 Suppl):S1-S37.

2. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003; 49(3 Suppl):S200-S210.

3. Vega B. Toll-like receptor-2: a novel mechanism of action of adapalene in the treatment of inflammatory acne lesions. Poster #84 presented at the 61st annual meeting of the American Academy of Dermatology, March 21-26, 2003, San Francisco, CA.

4. Wauben-Penris PJ, Cerneus DP, van den Hoven WE, et al. Immunomodulatory effects of tretinoin in combination with clindamycin. J Eur Acad Dermatol Venereol. 1998; 11 (Suppl 1):S2-7; discussion S28-9.

5. Kligman AM, Mills OH, McGinley KJ, et al. Acne therapy with tretinoin in combination with antibiotics. Acta Derm Venereol Suppl (Stockh). 1975; 74:111-115.

6. Shalita A, Miller B, Menter A, et al. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol. 2005; 4(2):153-158.

7. Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002; 69(2 Suppl):4-11.

8. Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002; 69(2 Suppl):12-19.

9. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(6 Suppl):4-9.

10. Warner GT, Plosker GL. Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne. Am J Clin Dermatol. 2002;3:349-360.

11. Taylor GA, Shalita AR. Benzoyl peroxide-based combination therapies for acne vulgaris. Am J Clin Dermatol. 2004;5:261-265.

12. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37:590-595.

13. Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24:1117-1133.